1 Description of the analysis objectives

2 **Objective 1. Description of socio-demographic and clinical characteristics**

Socio-demographic and clinical characteristics will be described for the population and pre-specified subgroups. Table 3 presents the description of the study variables with their respective descriptive statistics. Tables and graphs will be used to present the results.

7

Variable	Numerical summary
Age (continuous and categorical)	mean (SD) or median (IQR), when
< 18 years old	continuous and n/N (%), when
0-4 years	categorical
5-13 years	
14-17 years	
18-45 years	
46-65 years	
66-75 years	
> 75 years old	
Gender	
Male, female	n/N (%)
If female, pregnancy status	
Anthropometry and vital signs on	
admission Temperature (continuous	
and categorical > 37.5°C)	mean (SD) or median (IQR), when
Heart rate (continuous and categorical	continuous and n/N (%), when
> 100 p/ min in adults and adolescents;	categorical mean (SD) or median
> 120 in children up to 12 years)	(IQR), when continuous and n/N (%),
Respiration rate (continuous and	when categorical
categorical > 20 r/min in adults and	
adolescents; > 40 in children up to	mean (SD) or median (IQR), when
12 years)	continuous and n/N (%), when
Blood pressure (continuous and	categorical
categorical systolic > 140 mmHg in	
adults) Oxygen saturation	
(continuous and categorical: <90%,	mean (SD) or median (IQR), when
<94%)	continuous and n/N (%), when
	categorical mean (SD) or median
	(IQR), when continuous and n/N (%),
	when categorical

Table 3. Study variables and their values or categories and numerical summary

Oxygen saturation in room air/oxygen ther	ару
(categorical)	
Glasgow Coma Scale	mean (SD) or median (IQR)
Height (cm)	mean (SD) or median (IQR)
Weight (kg)	mean (SD) or median (IQR)
BMI (continuous: kg/m ² and categorical:	mean (SD) or median (IQR), when
≥ 30;	continuous and n/N (%), when
≥ 40)	categorical
Obesity (BMI ≥ 30)	n/N (%)
Chronic conditions	n/N (%)
Chronic heart disease (not	
hypertension); Diabetes; Hypertension;	
Current smoker; Chronic lung disease;	
Tuberculosis; Asthma; Asplenia; Chronic	
kidney disease; Malignant neoplasm;	
Chronic liver disease (categorical	
Yes/No); Other (open text field)	
Pre-admission or chronic medications	n/N (%)
ACE inhibitors; ARBs; NSAIDs; Antiviral: (if	
yes, which:	
chloroquine/hydroxychloroquine,	
azithromycin, kaletra [lopinavir-ritonavir],	
favipiravir, Other)	
Signs and symptoms on admission and	n/N (%)
during nospitalization	
Laboratory examinations on admission	moon (SD) or modion (IOP)
and	mean (SD) of median (IQR)
during hospitalization	
Hemoglobin (g/L); Creatinine (mmol/L);	
White blood cell count (x10g/L); Sodium	
(mEq/L); Hematocrit (%); Potassium	
(mEq/L); Platelets (x10g/L); Procalcitonin	
(ng/mL); APTT/PT; CRP (mg/L); PT	
(seconds); LDH (U/L); INR; Creatine	

Troponin (ng/mL)(mEq/L); Total bilirubin	
(µmol/L); ESR (mm/hr); AST/SGOT (U/L);	
D-dimer (mg/L); Urea (mmol/L); Ferritin	
(ng/mL); Lactate (mmol/L)	
Treatments on admission and during	n/N (%)
hospitalization	
Antiviral (If Yes, which: Ribavirin,	
Lopinavir/Ritonavir, Neuraminidase	
Inhibitor, Interferon alpha, Interferon beta,	
Other; If Other, specify); Corticosteroids	
(If Yes, route: Oral, Intravenous, Inhaled;	
If Yes, specify agent; If Yes, provide	
maximum daily dose);	
Antibiotic; Antifungal agent; Antimalarial	
agent (If Yes, specify); Experimental	
agent (If Yes, specify); NSAID; ACE	
inhibitors; ARBs; Systemic	
anticoagulation	
Examination of the pathogen performed	
	n/N (%)
Concerning (If Desitive, specify type);	
Coronavirus (if Positive, specify type; if	
Other, specify); Other respiratory	
pathogen (If Positive, specify type); Hiv	
Hospitalization in ICU or High	
Dependency Unit	n/N (%)
Respiratory and intensive care	
	n/N (%)
Oxygen therapy; Invasive ventilation	n/N (%)
(any); Extracorporeal support (ECMO);	
Liver dystunction; Pronation; Renal	
replacement therapy (RRT) or dialysis;	
Inotropics/vasopressors	

Hospital outcome	
Discharge alive, Hospitalized,	n/N (%)
Transferred to another unit, Death,	
Palliative discharge, Unknown	
Complications during hospitalization	
Shock; Bacteremia; Convulsion;	n/N (%)
Bleeding; Meningitis/encephalitis;	
Endocarditis; Anemia;	
Myocarditis/pericarditis; Cardiac	
arrhythmia; Acute kidney injury; Cardiac	
arrest; Pancreatitis; Pneumonia; Liver	
dysfunction; Bronchiolitis;	
Cardiomyopathy (If Yes, specify)	
Time-to-event outcomes Symptom	
onset (day of disease on	median (IQR), mean (SD), survival
admission): days between first	curve (Kaplan-Meier)
symptom and admission Length of	
stay	
Length of stay in ICU	
Days from hospital admission to ICU	
admission	
Days from hospital admission to	
transfer or death (reported as total,	
for survivors and non-survivors)	
•	

Objective 2. Characterization of access profiles and hospital resource utilization patterns

The characteristics signs/symptoms, laboratory tests on admission, presence of chronic diseases, treatments received, and outcomes will be described for the population and pre-specified subgroups.

Objective 3. Association between clinical/socio-demographic characteristics and outcomes

Measures of association, such as *odds ratio* (OR), risk ratio (RR) or *hazard ratio* (HR), crude and adjusted for potential confounding variables will be estimated and 95% confidence intervals (95% CI) will be reported. Logistic regression (or Poisson models with robust variance) will be fitted for dichotomous outcomes. Cox proportional hazards models will be fitted for time-to-event outcomes. The assumptions of the regression models will be evaluated using goodness of fit statistics (likelihood and variance analysis) and residual analysis. The set of adjustment variables will be specified primarily by building theoretical models using causal diagrams (*directed acyclic graphs* - DAGs)^{5,6}.

Objective 4. Sources of inequities

The distribution of socio-demographic, clinical, and outcome characteristics will be described and compared between pre-specified subgroups. Crude association measures (OR, RR or HR, depending on the nature of the outcome) adjusted for potential confounding variables will be estimated and 95% CIs will be reported. The set of adjustment variables will be primarily specified by building theoretical models (DAGs).